bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table 1, Figures 1 - 3 from Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab
Authors: Hegde Priti S. , Jubb Adrian M. , Chen Dafeng , Li Nicole F. , Meng Y. Gloria , Bernaards Coen , Elliott Rebecca , Scherer Stefan J. , Chen Daniel S.
Published: April 2023

PDF file - 234K, Baseline demographics for patients with and without VEGF-A samples in the AVF2107, E4599, AVAiL, and AVOREN trials, The GEN.038 VEGF-A ELISA, Standard curves for different VEGF-A isoforms in the GEN.038 assay, Correlation of baseline plasma VEGF-A levels with patient and tumor characteristics from AVOREN
CCR Translation for This Article from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Authors: Finn Richard S. , Press Michael F. , Dering Judy , O'Rourke Lisa , Florance Allison , Ellis Catherine , Martin Anne-Marie , Johnston Stephen
Published: April 2023

CCR Translation for This Article from Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Supplementary Figure 1 from A Tumorigenic Factor Interactome Connected through Tumor Suppressor MicroRNA-198 in Human Pancreatic Cancer
Authors: Marin-Muller Christian , Li Dali , Bharadwaj Uddalak , Li Min , Chen Changyi , Hodges Sally E. , Fisher William E. , Mo Qianxing , Hung Mien-Chie , Yao Qizhi
Published: April 2023

Supplementary Figure 1 - PDF file 147K, Additional evidence that miR-198 is regulated by MSLN in PC cells
Supplementary Figure 2 from Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Authors: Kachala Stefan S. , Bograd Adam J. , Villena-Vargas Jonathan , Suzuki Kei , Servais Elliot L. , Kadota Kyuichi , Chou Joanne , Sima Camelia S. , Vertes Eva , Rusch Valerie W. , Travis William D. , Sadelain Michel , Adusumilli Prasad S.
Published: April 2023

PDF file - 139K, Supplementary Fig. S2. Decreased survival of mice bearing mesothelin (MSLN)(+) tumors is confirmed in a syngeneic and xenogeneic models of metastatic lung ADC.
Supplementary Table 1 from Topotecan and Doxorubicin Combination to Treat Recurrent Ovarian Cancer: The Influence of Drug Exposure Time and Delivery Systems to Achieve Optimum Therapeutic Activity
Authors: Patankar Nilesh A. , Pritchard Julia , van Grinsven Mariska , Osooly Maryam , Bally Marcel B.
Published: April 2023

PDF file - 72 KB, Mean IC50 values of topotecan and doxorubicin as assessed in ovarian cancer cell lines ES-2, SKOV-3 and OVCAR-3.
Supplementary Figure S2 from The Activation of the WNT Signaling Pathway Is a Hallmark in Neurofibromatosis Type 1 Tumorigenesis
Authors: Luscan Armelle , Shackleford Ghjuvan'Ghjacumu , Masliah-Planchon Julien , Laurendeau Ingrid , Ortonne Nicolas , Varin Jennifer , Lallemand François , Leroy Karen , Dumaine Valérie , Hivelin Mikael , Borderie Didier , De Raedt Thomas , Valeyrie-Allanore Laurence , Larousserie Frédérique , Terris Benoît , Lantieri Laurent , Vidaud Michel , Vidaud Dominique , Wolkenstein Pierre , Parfait Béatrice , Bièche Ivan , Massaad Charbel , Pasmant Eric
Published: April 2023

PDF file 92K, mRNA expression of WNT9A, WNT5A, SFRP4 and DKK1 in four tumor pairs (plexiform neurofibroma and matched MPNSTs from the same patient). For each gene, mRNA levels were normalized such that the median value of 7 dermal neurofibromas was 1
Related Article from Pertuzumab Protects the Achilles' Heel of Trastuzumab—Emtansine
Authors: Gwin William R. , Spector Neil L.
Published: April 2023

Related Article from Pertuzumab Protects the Achilles' Heel of Trastuzumab—Emtansine
Supplementary Figure S2 from Distinction between Asymptomatic Monoclonal B-cell Lymphocytosis with Cyclin D1 Overexpression and Mantle Cell Lymphoma: From Molecular Profiling to Flow Cytometry
Authors: Espinet Blanca , Ferrer Ana , Bellosillo Beatriz , Nonell Lara , Salar Antonio , Fernández-Rodríguez Concepción , Puigdecanet Eulàlia , Gimeno Javier , Garcia-Garcia Mar , Vela Maria Carmen , Luño Elisa , Collado Rosa , Navarro José Tomás , de la Banda Esmeralda , Abrisqueta Pau , Arenillas Leonor , Serrano Cristina , Lloreta Josep , Miñana Belén , Cerutti Andrea , Florensa Lourdes , Orfao Alberto , Sanz Ferran , Solé Francesc , Dominguez-Sola David , Serrano Sergio
Published: April 2023

PDF file 132K, Validation of gene expression analysis results by qRT-PCR
Supplementary Figure 1 from CD62L as a Therapeutic Target in Chronic Lymphocytic Leukemia
Authors: Burgess Melinda , Gill Devinder , Singhania Richa , Cheung Catherine , Chambers Lynne , Renyolds Brent A. , Smith Louise , Mollee Peter , Saunders Nicholas , McMillan Nigel AJ
Published: April 2023

Supplementary Figure 1 - PDF files 2472K, Expression of cell surface markers throughout CLL PBMC
Supplementary Figure 1 from The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression
Authors: Salvador Marion A. , Wicinski Julien , Cabaud Olivier , Toiron Yves , Finetti Pascal , Josselin Emmanuelle , Lelièvre Hélène , Kraus-Berthier Laurence , Depil Stéphane , Bertucci François , Collette Yves , Birnbaum Daniel , Charafe-Jauffret Emmanuelle , Ginestier Christophe
Published: April 2023

PDF file 166K, Identification of two drug-response groups using a Gaussian mixture model (GMM)
Supplementary Table S3 from Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Authors: Wu Wenjuan , Bi Chen , Credille Kelly M. , Manro Jason R. , Peek Victoria L. , Donoho Gregory P. , Yan Lei , Wijsman John A. , Yan S. Betty , Walgren Richard A.
Published: April 2023

Supplementary Table S3 - PDF file 94K, Phospho-protein array data
Supplementary Figure 1 from Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Authors: Coiffier Bertrand , Li Weimin , Henitz Erin D. , Karkera Jayaprakash D. , Favis Reyna , Gaffney Dana , Shapiro Alice , Theocharous Panteli , Elsayed Yusri A. , van de Velde Helgi , Schaffer Michael E. , Osmanov Evgenii A. , Hong Xiaonan , Scheliga Adriana , Mayer Jiri , Offner Fritz , Rule Simon , Teixeira Adriana , Romejko-Jarosinska Joanna , de Vos Sven , Crump Michael , Shpilberg Ofer , Zinzani Pier Luigi , Cakana Andrew , Esseltine Dixie-Lee , Mulligan George , Ricci Deborah
Published: April 2023

Supplementary Figure 1 PDF file 77K, Biomarker sample collection from the LYM-3001 intent-to-treat population
Fig. S9 from The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α–Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer
Authors: Heckmann Doreen , Maier Patrick , Laufs Stephanie , Li Li , Sleeman Jonathan P. , Trunk Marcus J. , Leupold Jörg H. , Wenz Frederik , Zeller W. Jens , Fruehauf Stefan , Allgayer Heike
Published: April 2023

PDF file 86K, S9: Effect of Plerixafor on SW480CXCR7 and SW480CXCR4/CXCR7 cells
Supplementary Figure 3 from Zoledronic Acid Has Differential Antitumor Activity in the Pre- and Postmenopausal Bone Microenvironment In Vivo
Authors: Ottewell Penelope D. , Wang Ning , Brown Hannah K. , Reeves Kimberly J. , Fowles C. Anne , Croucher Peter I. , Eaton Colby L. , Holen Ingunn
Published: April 2023

PDF file - 46KB, Effects of administration of PTH on a)osteoclast activity and b) tumour growth in bone.
Fig. S4 from The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α–Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer
Authors: Heckmann Doreen , Maier Patrick , Laufs Stephanie , Li Li , Sleeman Jonathan P. , Trunk Marcus J. , Leupold Jörg H. , Wenz Frederik , Zeller W. Jens , Fruehauf Stefan , Allgayer Heike
Published: April 2023

PDF file 121K, S4: Dose-response curves towards SDF-1a and I-TAC in Matrigel invasion assay
Related Article from Managing Breast Cancers with Low Estrogen Receptor and HER2 by Drugging Both
Authors: Miller Todd W.
Published: April 2023

Related Article from Managing Breast Cancers with Low Estrogen Receptor and HER2 by Drugging Both
Fig. S1 from The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α–Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer
Authors: Heckmann Doreen , Maier Patrick , Laufs Stephanie , Li Li , Sleeman Jonathan P. , Trunk Marcus J. , Leupold Jörg H. , Wenz Frederik , Zeller W. Jens , Fruehauf Stefan , Allgayer Heike
Published: April 2023

PDF file 57K, S1: Lentiviral vectors for expression of CXCR4 and CXCR7
Legend to Figure S1 from Effects of Adjuvant Chemoradiotherapy on the Frequency and Function of Regulatory T Cells in Patients with Head and Neck Cancer
Authors: Schuler Patrick J. , Harasymczuk Malgorzata , Schilling Bastian , Saze Zenichiro , Strauss Laura , Lang Stephan , Johnson Jonas T. , Whiteside Theresa L.
Published: April 2023

PDF file 34K, Describes the content of Figure S1
Supplementary Methods from Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy
Authors: Phillips Gail D. Lewis , Fields Carter T. , Li Guangmin , Dowbenko Donald , Schaefer Gabriele , Miller Kathy , Andre Fabrice , Burris Howard A. , Albain Kathy S. , Harbeck Nadia , Dieras Veronique , Crivellari Diana , Fang Liang , Guardino Ellie , Olsen Steven R. , Crocker Lisa M. , Sliwkowski Mark X.
Published: April 2023

PDF file 86K, Supplementary Methods and figure legends
Supplementary Tables 1 - 5 from The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma
Authors: Peled Amnon , Abraham Michal , Avivi Irit , Rowe Jacob M. , Beider Katia , Wald Hanna , Tiomkin Lena , Ribakovsky Lena , Riback Yossi , Ramati Yaron , Aviel Sigal , Galun Eithan , Shaw Howard Laurence , Eizenberg Orly , Hardan Izhar , Shimoni Avichai , Nagler Arnon
Published: April 2023

PDF file - 132K, Supplementary Table 1. Demographic characteristics of human patients. Supplementary Table 2. History of MM Therapy/Chemotherapy. Supplementary Table 3. Time from BKT140 dosing to first Stem cell (CD34+) collection and the number of stem cells collected at the first aphaeresis following administration of BKT140. Supplementary Table 4. Number of WBC and CD34+ cells in the blood pre dosing and post dosing with BKT140. Supplementary Table 5. Inclusion Criteria.
Supplementary Figure Legends, Figures 1 - 14 from Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy
Authors: Li Bin , Tsao Sai Wah , Chan Kwok Wah , Ludwig Dale L. , Novosyadlyy Ruslan , Li Yuk Yin , He Qing Yu , Cheung Annie L.M.
Published: April 2023

PDF file - 1419KB Supplementary Fig S1. Human growth factor antibody array analysis of the conditioned media from HKESC-3-CON and HKESC-3-Id1 cells. Supplementary Fig S2. Effect of knockdown Id1 expression on IGF2 level using a second RNAi sequence. Supplementary Fig S3. Effect of ectopic Id1 expression on IGF2 level in multiple cancer types. Supplementary Fig S4. Effect of Id1 manipulation on IGF2 mRNA expression in ESCC cells. Supplementary Fig S5. IGF2, Id1, and p-AKT expressions in human esophageal cancer. Supplementary Fig S6. Western blot analysis of Id1 and IGF2 expressions in ESCC cell lines. Supplementary Fig S7. Effects of Id1 knockdown on autocrine stimulation of esophageal cancer cell proliferation, migration, and survival. Supplementary Fig S8. Ki-67 and TUNEL staining of tumor xenografts from three groups of mice inoculated with KYSE150-CON-shCON, KYSE150-Id1-shCON, and KYSE150-Id1- shIGF2 cells, respectively. Supplementary Fig S9. Ki-67 and TUNEL staining in "responder" tumors of different groups of mice bearing KYSE150-CON-shCON, KYSE150-Id1-shCON, and KYSE150-Id1- shIGF2 "instigating" tumors, respectively. Supplementary Fig S10. Anti-tumor effects of IGF2-neutralizing antibody in vivo. Supplementary Fig S11. Immunohistochemical analysis of tumor xenografts treated with cixutumumab or the isotype IgG. Supplementary Fig S12. TUNEL staining of tumor xenografts from two groups of mice inoculated with KYSE150 (A) and KYSE270 (B) respectively. Supplementary Fig S13. Evaluation of toxic effects of cixutumumab in nude mice. A, comparison of body weight of cixutumumab-treated mice and isotype IgG-treated control mice. B, histological examination of lung, liver and kidney specimens (H&E stained). Supplementary Fig S14. Increased thymidylate synthase expression in FR cells was inhibited by cixutumumab.
Supplementary Table 1 from Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer
Authors: Schuler Patrick J. , Harasymczuk Malgorzata , Visus Carmen , DeLeo Albert , Trivedi Sumita , Lei Yu , Argiris Athanassios , Gooding William , Butterfield Lisa H. , Whiteside Theresa L. , Ferris Robert L.
Published: April 2023

PDF file - 58KB, Treatment arms as specified in the protocol.
Supplementary Table 1 from Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts
Authors: Kimple Randall J. , Harari Paul M. , Torres Alexandra D. , Yang Robert Z. , Soriano Benjamin J. , Yu Menggang , Armstrong Eric A. , Blitzer Grace C. , Smith Molly A. , Lorenz Laurel D. , Lee Denis , Yang David T. , McCulloch Timothy M. , Hartig Gregory K. , Lambert Paul F.
Published: April 2023

XLSX file - 37K, Primer sequences used.
Supplementary Figure 1 from High Phospho-Stathmin(Serine38) Expression Identifies Aggressive Endometrial Cancer and Suggests an Association with PI3K Inhibition
Authors: Wik Elisabeth , Birkeland Even , Trovik Jone , Werner Henrica M.J. , Hoivik Erling A. , Mjos Siv , Krakstad Camilla , Kusonmano Kanthida , Mauland Karen , Stefansson Ingunn M. , Holst Frederik , Petersen Kjell , Oyan Anne M. , Simon Ronald , Kalland Karl H. , Ricketts William , Akslen Lars A. , Salvesen Helga B.
Published: April 2023

PDF file - 49K, pStathmin(S38) identifies patients with different prognosis in subgroups of patients with expected good survival.
Supplementary Figure S1 from Contrasting Expression Patterns of Histone mRNA and microRNA 760 in Patients with Gastric Cancer
Authors: Iwaya Takeshi , Fukagawa Takeo , Suzuki Yutaka , Takahashi Yusuke , Sawada Genta , Ishibashi Masahisa , Kurashige Junji , Sudo Tomoya , Tanaka Fumiaki , Shibata Kohei , Endo Fumitaka , Katagiri Hirokatsu , Ishida Kaoru , Kume Kohei , Nishizuka Satoshi , Iinuma Hisae , Wakabayashi Go , Mori Masaki , Sasako Mitsuru , Mimori Koshi
Published: April 2023

PDF file 3876K, The association between histone mRNA and miR-760 in GC cells
Supplementary Figure 2 from In Vivo Fluorescence Lifetime Imaging for Monitoring the Efficacy of the Cancer Treatment
Authors: Ardeshirpour Yasaman , Chernomordik Victor , Hassan Moinuddin , Zielinski Rafal , Capala Jacek , Gandjbakhche Amir
Published: April 2023

PDF file - 1178KB, Difference between fluorescence lifetimes at the tumor and contralateral sites (ns) vs. (a) tumor size (b) tumor depth, 6 hours after injection of Affibody probe.
Supplementary Table S7 from Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer
Authors: Dai Wei , Zeller Constanze , Masrour Nahal , Siddiqui Nadeem , Paul James , Brown Robert
Published: April 2023

Supplementary Table S7 - PDF file 90K, Methylation and response
Supplementary Table S6 from Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer
Authors: Dai Wei , Zeller Constanze , Masrour Nahal , Siddiqui Nadeem , Paul James , Brown Robert
Published: April 2023

Supplementary Table S6 - PDF file 71K, PFS analysis in TCGA cohort
Supplementary Table S2 from Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer
Authors: Dai Wei , Zeller Constanze , Masrour Nahal , Siddiqui Nadeem , Paul James , Brown Robert
Published: April 2023

Supplementary Table S2 - PDF file 79K, Clinical Paramaters associated with PFS and OS
Supplementary Table 1 from Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization
Authors: McCune Jeannine S. , Bemer Meagan J. , Barrett Jeffrey S. , Scott Baker K. , Gamis Alan S. , Holford Nicholas H.G.
Published: April 2023

PDF file 62K, Prior population pharmacokinetic models and initial dosing for children receiving IV busulfan
Supplementary Figure 3 from Reciprocal Interactions between Tumor-Associated Macrophages and CD44-Positive Cancer Cells via Osteopontin/CD44 Promote Tumorigenicity in Colorectal Cancer
Authors: Rao Guanhua , Wang Hongyi , Li Baowei , Huang Li , Xue Danfeng , Wang Xiaohui , Jin Haijing , Wang Jun , Zhu Yushan , Lu Youyong , Du Lei , Chen Quan
Published: April 2023

PDF file - 1232K, OPN promote clonogenicity of HT-29 cells on different concentrations.
Supplementary Figure 5 from Cabozantinib Inhibits Prostate Cancer Growth and Prevents Tumor-Induced Bone Lesions
Authors: Dai Jinlu , Zhang Honglai , Karatsinides Andreas , Keller Jill M. , Kozloff Kenneth M. , Aftab Dana T. , Schimmoller Frauke , Keller Evan T.
Published: April 2023

PDF file 183K, Impact of cabozantinib on MET, phospho-MET, VEGFR2 and phospho-VEGFR2 expression of subcutaneous and intratibial PC-3 tumors in mice
Supplementary Table 1 from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Authors: O'Brien Neil A. , McDonald Karen , Tong Luo , von Euw Erika , Kalous Ondrej , Conklin Dylan , Hurvitz Sara A. , di Tomaso Emmanuelle , Schnell Christian , Linnartz Ronald , Finn Richard S. , Hirawat Samit , Slamon Dennis J.
Published: April 2023

XLSX file - 14K, Table S1: Calculated IC50s for the PI3K/mTOR pathway inhibitors against the breast cancer cell line panel. ER: Estrogen Receptor. N/A: IC50 not achieved, N/D: IC50 not determined
Supplementary Figure S7 from Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis
Authors: Hinrichsen Inga , Brieger Angela , Trojan Jörg , Zeuzem Stefan , Nilbert Mef , Plotz Guido
Published: April 2023

PDF file - 153 KB, MutL� structure and the effects of substitutions on repair. The MutL� structural model is shown as described in Supplementary Figure S6. The location of all residues whose substitutions have been investigated in this study are shown as spheres of their respective C� atoms, color-coded by repair efficiency as determined in the experiments. Known major catalytic activities and their approximate location are shown on the structure by black boxes.
Supplementary Methods from Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT
Authors: O'Brien Neil A. , McDonald Karen , Tong Luo , von Euw Erika , Kalous Ondrej , Conklin Dylan , Hurvitz Sara A. , di Tomaso Emmanuelle , Schnell Christian , Linnartz Ronald , Finn Richard S. , Hirawat Samit , Slamon Dennis J.
Published: April 2023

PDF file - 60K
Supplementary Figure 3 from Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma
Authors: Jones Kimberley , Nourse Jamie P. , Keane Colm , Bhatnagar Atul , Gandhi Maher K.
Published: April 2023

PDF file - 33K, Figure S3. Circulating miRNA are not significantly influenced by time from collection to processing.
Supplementary Table 2 from Identification of Lethal microRNAs Specific for Head and Neck Cancer
Authors: Lindenbergh-van der Plas Marlon , Martens-de Kemp Sanne R. , de Maaker Michiel , van Wieringen Wessel N. , Ylstra Bauke , Agami Reuven , Cerisoli Francesco , Leemans C. René , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file, 732K, Differentially expressed genes group A microRNAs.
Supplementary Figure Legend from BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
Authors: Frederick Dennie T. , Piris Adriano , Cogdill Alexandria P. , Cooper Zachary A. , Lezcano Cecilia , Ferrone Cristina R. , Mitra Devarati , Boni Andrea , Newton Lindsay P. , Liu Chengwen , Peng Weiyi , Sullivan Ryan J. , Lawrence Donald P. , Hodi F. Stephen , Overwijk Willem W. , Lizée Gregory , Murphy George F. , Hwu Patrick , Flaherty Keith T. , Fisher David E. , Wargo Jennifer A.
Published: April 2023

PDF file - 69K
Supplementary Data 2 from Adoptive Transfer of Autologous T Cells Improves T-cell Repertoire Diversity and Long-term B-cell Function in Pediatric Patients with Neuroblastoma
Authors: Grupp Stephan A. , Prak Eline Luning , Boyer Jean , McDonald Kenyetta R. , Shusterman Suzanne , Thompson Edward , Callahan Colleen , Jawad Abbas F. , Levine Bruce L. , June Carl H. , Sullivan Kathleen E.
Published: April 2023

PDF file - 435K, Representative flow cytometry plots
Supplementary Figure 2 from Impairment of Glioma Stem Cell Survival and Growth by a Novel Inhibitor for Survivin–Ran Protein Complex
Authors: Guvenc Hacer , Pavlyukov Marat S. , Joshi Kaushal , Kurt Habibe , Banasavadi-Siddegowda Yeshavanth K. , Mao Ping , Hong Christopher , Yamada Ryosuke , Kwon Chang-Hyuk , Bhasin Deepak , Chettiar Somsundaram , Kitange Gaspar , Park In-Hee , Sarkaria Jann N. , Li Chenglong , Shakhparonov Mihail I. , Nakano Ichiro
Published: April 2023

PDF file - 7900K, Immunocytochemstry of Survivin (related to Figure 2)
Supplementary Methods and Figure Legends from An Unconventional KITENIN/ErbB4-Mediated Downstream Signal of EGF Upregulates c-Jun and the Invasiveness of Colorectal Cancer Cells
Authors: Bae Jeong A. , Yoon Somy , Park So-Yeon , Lee Jae Hyuk , Hwang Jun-Eul , Kim Hangun , Seo Young-Woo , Cha Yoon Jin , Hong Sung Pil , Kim Hoguen , Chung Ik Joo , Kim Kyung Keun
Published: April 2023

PDF file - 456K
Supplementary Methods from Coadministration of Epithelial Junction Opener JO-1 Improves the Efficacy and Safety of Chemotherapeutic Drugs
Authors: Beyer Ines , Cao Hua , Persson Jonas , Song Hui , Richter Maximilian , Feng Qinghua , Yumul Roma , van Rensburg Ruan , Li Zongyi , Berenson Ronald , Carter Darrick , Roffler Steve , Drescher Charles , Lieber André
Published: April 2023

PDF file - 55K
Supplementary Figure 2 from Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer
Authors: Aruga Atsushi , Takeshita Nobuhiro , Kotera Yoshihito , Okuyama Ryuji , Matsushita Norimasa , Ohta Takehiro , Takeda Kazuyoshi , Yamamoto Masakazu
Published: April 2023

PDF File - 125K, An algorithm to define the responses of antigen-specific T cells by using the ELISPOT assay.
Supplementary table 2 from Altered DNA Methylation Landscapes of Polycomb-Repressed Loci Are Associated with Prostate Cancer Progression and ERG Oncogene Expression in Prostate Cancer
Authors: Kron Ken , Trudel Dominique , Pethe Vaijayanti , Briollais Laurent , Fleshner Neil , van der Kwast Theodorus , Bapat Bharati
Published: April 2023

Supplementary table 2 XLSX file 17K, Clinicopathological data including GS, pathological stage, and ERG expression data for cohort cancer specimens
Supplementary Figure 4 from DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression
Authors: Hsieh Mei-Yi , Fan Jia-Rong , Chang Han-Wen , Chen Hsiang-Chin , Shen Tang-Long , Teng Shu-Chun , Yeh Yen-Hsiu , Li Tsai-Kun
Published: April 2023

PDF file 2097K, Knockdown of hTOP3alpha and p53, but not BLM, reduced cellular senescence and enhanced anchorage-independent growth of AGS cells
Supplementary Figure 1 from DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression
Authors: Hsieh Mei-Yi , Fan Jia-Rong , Chang Han-Wen , Chen Hsiang-Chin , Shen Tang-Long , Teng Shu-Chun , Yeh Yen-Hsiu , Li Tsai-Kun
Published: April 2023

PDF file 2053K, DNA damage-induced expression of p53, p5315P and p21 is greatly reduced in hTOP3α-deficient cells
Supplementary Figure 1 from Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
Authors: Wrangle John , Machida Emi Ota , Danilova Ludmila , Hulbert Alicia , Franco Noreli , Zhang Wei , Glöckner Sabine C. , Tessema Mathewos , Van Neste Leander , Easwaran Hariharan , Schuebel Kornel E. , Licchesi Julien , Hooker Craig M. , Ahuja Nita , Amano Jun , Belinsky Steven A. , Baylin Stephen B. , Herman James G. , Brock Malcolm V.
Published: April 2023

PDF file - 2177KB, Scatter Plots of Gene Re-expression with Decitabine or Trichostatin-A in Eight Non-Small Cell Lung Cancer Cell Lines.
Supplementary Figure 2 from A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Authors: Beatty Gregory L. , Torigian Drew A. , Chiorean E. Gabriela , Saboury Babak , Brothers Alex , Alavi Abass , Troxel Andrea B. , Sun Weijing , Teitelbaum Ursina R. , Vonderheide Robert H. , O'Dwyer Peter J.
Published: April 2023

Supplementary Figure 2 - PDF file 71K, Analysis of cytokines as correlatives of overall survival
Supplementary Figure 1 from A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Authors: Beatty Gregory L. , Torigian Drew A. , Chiorean E. Gabriela , Saboury Babak , Brothers Alex , Alavi Abass , Troxel Andrea B. , Sun Weijing , Teitelbaum Ursina R. , Vonderheide Robert H. , O'Dwyer Peter J.
Published: April 2023

Supplementary Figure 1 - PDF file 99K, Pharmacodynamic effects of gemcitabine and CP-870,893
Supplementary Data from Phase I Pharmacokinetic and Pharmacodynamic Study of the First-in-Class Spliceosome Inhibitor E7107 in Patients with Advanced Solid Tumors
Authors: Eskens Ferry A.L.M. , Ramos Francisco J. , Burger Herman , O'Brien James P. , Piera Adelaida , de Jonge Maja J.A. , Mizui Yoshiharu , Wiemer Erik A.C. , Carreras Maria Josepa , Baselga José , Tabernero Josep
Published: April 2023

Supplementary Data - PDF file 104K, Supplementary Data: Eligibility criteria and Pharmacodynamic analysis: methodology sections
Supplementary Figure 3 from Functional Genetic Screens Identify Genes Essential for Tumor Cell Survival in Head and Neck and Lung Cancer
Authors: Martens-de Kemp Sanne R. , Nagel Remco , Stigter-van Walsum Marijke , van der Meulen Ida H. , van Beusechem Victor W. , Braakhuis Boudewijn J.M. , Brakenhoff Ruud H.
Published: April 2023

PDF file - 66K, KIF11 mRNA targeting siRNAs establish good knockdown of gene expression.
Supplementary Materials and Methods, Figure Legends from Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs
Authors: Patwardhan Parag P. , Surriga Oliver , Beckman Michael J. , de Stanchina Elisa , Dematteo Ronald P. , Tap William D. , Schwartz Gary K.
Published: April 2023

PDF file - 121KB
Supplementary Figures 1 - 2 from Sustained Inhibition of Receptor Tyrosine Kinases and Macrophage Depletion by PLX3397 and Rapamycin as a Potential New Approach for the Treatment of MPNSTs
Authors: Patwardhan Parag P. , Surriga Oliver , Beckman Michael J. , de Stanchina Elisa , Dematteo Ronald P. , Tap William D. , Schwartz Gary K.
Published: April 2023

PDF file - 198KB, Basal expression levels of c-Fms and c-Kit in sarcoma cell lines and Effect of siRNA mediated knockdown on cell proliferation.
Supplementary Table 1 from Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets
Authors: Stefanska Barbara , Cheishvili David , Suderman Matthew , Arakelian Ani , Huang Jian , Hallett Michael , Han Ze-Guang , Al-Mahtab Mamun , Akbar Sheikh Mohammad Fazle , Khan Wasif Ali , Raqib Rubhana , Tanvir Imrana , Khan Haseeb Ahmed , Rabbani Shafaat A. , Szyf Moshe
Published: April 2023

XLS file - 32KB, Supplementary Table S1. List of siRNAs, shRNAs, primer sequences used in expression analysis (QPCR) and pyrosequencing.
Supplementary Figure 4 from Myeloid Differentiation Factor 88 Promotes Growth and Metastasis of Human Hepatocellular Carcinoma
Authors: Liang Beibei , Chen Rui , Wang Tao , Cao Lei , Liu Yingying , Yin Fan , Zhu Minhui , Fan Xiaoyu , Liang Yingchao , Zhang Lu , Guo Yajun , Zhao Jian
Published: April 2023

PDF File - 656K, Inhibition of MEK-ERK pathway reduced promotion of MyD88 in the migration of HCC cells. And inhibition of IL-6 also reduced promotion of MyD88 in the migration of HCC cells, but not in one's proliferation.
Supplementary table S3 from Interobserver Agreement in Describing the Ultrasound Appearance of Adnexal Masses and in Calculating the Risk of Malignancy Using Logistic Regression Models
Authors: Sladkevicius Povilas , Valentin Lil
Published: April 2023

Supplementary table S3. It describes which variables describing the adnexal masses differed between two observes when estimated risk was >25 percentage units using logistic regression model 2 (LR2)
Supplementary material and methods re-revised from WRN Promoter CpG Island Hypermethylation Does Not Predict More Favorable Outcomes for Patients with Metastatic Colorectal Cancer Treated with Irinotecan-Based Therapy
Authors: Bosch Linda J.W. , Luo Yanxin , Lao Victoria V. , Snaebjornsson Petur , Trooskens Geert , Vlassenbroeck Ilse , Mongera Sandra , Tang Weiliang , Welcsh Piri , Herman James G. , Koopman Miriam , Nagtegaal Iris D. , Punt Cornelis J.A. , van Criekinge Wim , Meijer Gerrit A. , Monnat Raymond J. , Carvalho Beatriz , Grady William M.
Published: April 2023

Detailed description of material and methods used
Supplemental Figure 2 from Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma
Authors: Kawai Takayuki , Yasuchika Kentaro , Ishii Takamichi , Katayama Hokahiro , Yoshitoshi Elena Yukie , Ogiso Satoshi , Kita Sadahiko , Yasuda Katsutaro , Fukumitsu Ken , Mizumoto Masaki , Hatano Etsuro , Uemoto Shinji
Published: April 2023

Supplemental Figure 2. Cancer stem cell properties of K19+ PLC/PRF/5 and Hep3B cells in vitro
Figure S1 from Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer
Authors: Lee Keun-Wook , Lee Sung Sook , Hwang Jun-Eul , Jang Hee-Jin , Lee Hyun-Sung , Oh Sang Cheul , Lee Sang Ho , Sohn Bo Hwa , Kim Sang Bae , Shim Jae-Jun , Jeong Woojin , Cha Minse , Cheong Jae-Ho , Cho Jae Yong , Lim Jae Yun , Park Eun Sung , Kim Sang Cheol , Kang Yoon-Koo , Noh Sung Hoon , Ajani Jaffer A. , Lee Ju-Seog
Published: April 2023

Expression of YAP1 in gastric cancer cells.
Supplemental Figure 2 from NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma
Authors: Huang Junwei , Zhou Yi , Thomas Gregory S. , Gu Zhimin , Yang Ye , Xu Hongwei , Tricot Guido , Zhan Fenghuang
Published: April 2023

Supplemental Figure 2. Representative senescence images. A, Representative images of the senescence experiments depicted in Figures 1D, 1E, and 4D.
Supplemental Figure 1 from NEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma
Authors: Huang Junwei , Zhou Yi , Thomas Gregory S. , Gu Zhimin , Yang Ye , Xu Hongwei , Tricot Guido , Zhan Fenghuang
Published: April 2023

Supplemental Figure 1. Uncropped immunoblots. Uncropped images of the immunoblots presented in Figures 2A, 2B, and 2C.
Supplementary Table 1 from A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors
Authors: Wagner Andrew J. , Messersmith Wells A. , Shaik M. Naveed , Li Sherry , Zheng Xianxian , McLachlan Karen R. , Cesari Rossano , Courtney Rachel , Levin Wendy J. , El-Khoueiry Anthony B.
Published: April 2023

Supplementary Table 1. Table summarizing Treatment-emergent all-cause AEs experienced by {greater than or equal to}5% of patients
Supplementary Table 5 and 6 from FGFR1/3 Tyrosine Kinase Fusions Define a Unique Molecular Subtype of Non–Small Cell Lung Cancer
Authors: Wang Rui , Wang Lei , Li Yuan , Hu Haichuan , Shen Lei , Shen Xuxia , Pan Yunjian , Ye Ting , Zhang Yang , Luo Xiaoyang , Zhang Yiliang , Pan Bin , Li Bin , Li Hang , Zhang Jie , Pao William , Ji Hongbin , Sun Yihua , Chen Haiquan
Published: April 2023

Table 5:Correlation between FGFR fusion and expression Table 6: Clinicopathologic Characteristics of 734 Patients with NSCLC in Survival analysis
Supplementary Table S6 from Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K–AKT–mTOR Pathway Inhibitors
Authors: Kong Yan , Si Lu , Li Yiqian , Wu Xiaowen , Xu Xiaowei , Dai Jie , Tang Huan , Ma Meng , Chi Zhihong , Sheng Xinan , Cui Chuanliang , Guo Jun
Published: April 2023

Supplementary Table S6. Statistical analysis of the effects of PI3K-AKT-mTOR inhibitors on proliferation of HEK293T cells bearing mTOR mutation.
Supplementary Data from Loss-of-Function Mutations in Calcitonin Receptor (CALCR) Identify Highly Aggressive Glioblastoma with Poor Outcome
Authors: Pal Jagriti , Patil Vikas , Kumar Anupam , Kaur Kavneet , Sarkar Chitra , Somasundaram Kumaravel
Published: April 2023

Supplementary Legends Supplementary Information Supplementary Methods
Supplementary Table 4 from Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers
Authors: Magbanua Mark Jesus M. , Carey Lisa A. , DeLuca Amy , Hwang Jimmy , Scott Janet H. , Rimawi Mothaffar F. , Mayer Erica L. , Marcom P. Kelly , Liu Minetta C. , Esteva Francisco J. , Park John W. , Rugo Hope S.
Published: April 2023

Supplementary Table 4. Proportional hazard Cox multivariate regression models to estimate risk of progression or death for dichotomized groups based on circulating tumor cell (CTC) status. Patients were assigned to the following groups: favorable (3.8) and IE/FC (p{less than or equal to}0.0049, HR=2.7). Models #1 and #2 revealed borderline significance for patients who were defined as favorable to unfavorable via CellSearch using either cutoff (p=0.0631, HR=2.4 and p=0.0520, HR=7.8).
Table S3 from Sequence Variation in Mature MicroRNA-499 Confers Unfavorable Prognosis of Lung Cancer Patients Treated with Platinum-Based Chemotherapy
Authors: Qiu Fuman , Yang Lei , Ling Xiaoxuan , Yang Rongrong , Yang Xiaorong , Zhang Lisha , Fang Wenxiang , Xie Chenli , Huang Dongsheng , Zhou Yifeng , Lu Jiachun
Published: April 2023

Table S3. Sequence of primers used in real time RT-PCR analysis.
Supplemental R File 4-UK TMA from Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer
Authors: Hunt Kelly K. , Karakas Cansu , Ha Min Jin , Biernacka Anna , Yi Min , Sahin Aysegul A. , Adjapong Opoku , Hortobagyi Gabriel N. , Bondy Melissa L. , Thompson Patricia A. , Cheung Kwok Leung , Ellis Ian O. , Bacus Sarah , Symmans W. Fraser , Do Kim-Anh , Keyomarsi Khandan
Published: April 2023

R File codes pertaining to UK cohort
Supplementary Table and Figure Legends from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Authors: Connolly Roisin M. , Li Huili , Jankowitz Rachel C. , Zhang Zhe , Rudek Michelle A. , Jeter Stacie C. , Slater Shannon A. , Powers Penny , Wolff Antonio C. , Fetting John H. , Brufsky Adam , Piekarz Richard , Ahuja Nita , Laird Peter W. , Shen Hui , Weisenberger Daniel J. , Cope Leslie , Herman James G. , Somlo George , Garcia Agustin A. , Jones Peter A. , Baylin Stephen B. , Davidson Nancy E. , Zahnow Cynthia A. , Stearns Vered
Published: April 2023

Supplementary Table and Figure Legends
Supplementary Table 2 from Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study
Authors: Connolly Roisin M. , Li Huili , Jankowitz Rachel C. , Zhang Zhe , Rudek Michelle A. , Jeter Stacie C. , Slater Shannon A. , Powers Penny , Wolff Antonio C. , Fetting John H. , Brufsky Adam , Piekarz Richard , Ahuja Nita , Laird Peter W. , Shen Hui , Weisenberger Daniel J. , Cope Leslie , Herman James G. , Somlo George , Garcia Agustin A. , Jones Peter A. , Baylin Stephen B. , Davidson Nancy E. , Zahnow Cynthia A. , Stearns Vered
Published: April 2023

Characterization of pre and post tx biopsies using Genefu and the PAM50 dataset. Paired biopsies (16/19) match with the clinical subtype of the patient's tumor at diagnosis. Treatment did not affect PAM50 subtype. Tx: therapy; HR: hormone-resistant; TNBC: triple-negative breast cancer.
Supplementary Table S1 from Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
Authors: Stelloo Ellen , Nout Remi A. , Osse Elisabeth M. , Jürgenliemk-Schulz Ina J. , Jobsen Jan J. , Lutgens Ludy C. , van der Steen-Banasik Elzbieta M. , Nijman Hans W. , Putter Hein , Bosse Tjalling , Creutzberg Carien L. , Smit Vincent T.H.B.M.
Published: April 2023

Clinicopathological characteristics of the PORTEC-1 and -2 trial populations: comparison of cases included in the current analysis and those excluded for lack of material (n=164), non-endometrioid histology (n=30) or failed molecular analysis (n=86).
Supplemental figure 3 from Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy
Authors: Thielen Noortje , Richter Johan , Baldauf Matthias , Barbany Gisela , Fioretos Thoas , Giles Francis , Gjertsen Bjørn-Tore , Hochhaus Andreas , Schuurhuis Gerrit Jan , Sopper Sieghart , Stenke Leif , Thunberg Sarah , Wolf Dominik , Ossenkoppele Gert , Porkka Kimmo , Janssen Jeroen , Mustjoki Satu
Published: April 2023

LSC analysis at 3 months time point by FISH
Supplemental figure 2 from Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy
Authors: Thielen Noortje , Richter Johan , Baldauf Matthias , Barbany Gisela , Fioretos Thoas , Giles Francis , Gjertsen Bjørn-Tore , Hochhaus Andreas , Schuurhuis Gerrit Jan , Sopper Sieghart , Stenke Leif , Thunberg Sarah , Wolf Dominik , Ossenkoppele Gert , Porkka Kimmo , Janssen Jeroen , Mustjoki Satu
Published: April 2023

Consort diagram
Supplementary Materials and Methods from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer
Authors: Xu Jian-Ming , Wang Yan , Wang You-Liang , Liu Tao , Ni Ming , Li Man-Sheng , Lin Li , Ge Fei-Jiao , Gong Chun , Gu Jun-Yan , Jia Ru , Wang He-Fei , Chen Yu-Ling , Liu Rong-Rui , Zhao Chuan-Hua , Tan Zhao-Li , Jin Yang , Zhu Yun-Ping , Ogino Shuji , Qian Zhi-Rong
Published: April 2023

Supplementary materials, methods and results
Supplementary Video 1 from Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer
Authors: Rosenthal Eben L. , Moore Lindsay S. , Tipirneni Kiranya , de Boer Esther , Stevens Todd M. , Hartman Yolanda E. , Carroll William R. , Zinn Kurt R. , Warram Jason M.
Published: April 2023

Representative video is shown of open-field imaging during intraoperative neck dissection from the 25mg/m2 dose cohort.
Table S2 from Evolution of Cytogenetically Normal Acute Myeloid Leukemia During Therapy and Relapse: An Exome Sequencing Study of 50 Patients
Authors: Greif Philipp A. , Hartmann Luise , Vosberg Sebastian , Stief Sophie M. , Mattes Raphael , Hellmann Ines , Metzeler Klaus H. , Herold Tobias , Bamopoulos Stefanos A. , Kerbs Paul , Jurinovic Vindi , Schumacher Daniela , Pastore Friederike , Bräundl Kathrin , Zellmeier Evelyn , Ksienzyk Bianka , Konstandin Nikola P. , Schneider Stephanie , Graf Alexander , Krebs Stefan , Blum Helmut , Neumann Martin , Baldus Claudia D. , Bohlander Stefan K. , Wolf Stephan , Görlich Dennis , Berdel Wolfgang E. , Wörmann Bernhard J. , Hiddemann Wolfgang , Spiekermann Karsten
Published: April 2023

Detailed patient characteristics
Supplementary legend from Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence
Authors: Ibrahimpasic Tihana , Xu Bin , Landa Iñigo , Dogan Snjezana , Middha Sumit , Seshan Venkatraman , Deraje Shyam , Carlson Diane L. , Migliacci Jocelyn , Knauf Jeffrey A. , Untch Brian , Berger Michael F. , Morris Luc , Tuttle R. Michael , Chan Timothy , Fagin James A. , Ghossein Ronald , Ganly Ian
Published: April 2023

Supplementary legend
Supplementary Methods from The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas
Authors: Ng Charlotte K.Y. , Piscuoglio Salvatore , Geyer Felipe C. , Burke Kathleen A. , Pareja Fresia , Eberle Carey A. , Lim Raymond S. , Natrajan Rachael , Riaz Nadeem , Mariani Odette , Norton Larry , Vincent-Salomon Anne , Wen Y. Hannah , Weigelt Britta , Reis-Filho Jorge S.
Published: April 2023

File containing the Supplementary Methods.
Supplementary Figures from Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model
Authors: Niemann Carsten U. , Mora-Jensen Helena I. , Dadashian Eman L. , Krantz Fanny , Covey Todd , Chen Shih-Shih , Chiorazzi Nicholas , Izumi Raquel , Ulrich Roger , Lannutti Brian J. , Wiestner Adrian , Herman Sarah E.M.
Published: April 2023

Supplementary Figures 1-4
Table S1 from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
Authors: Humphries Matthew P. , Sundara Rajan Sreekumar , Droop Alastair , Suleman Charlotte A.B. , Carbone Carmine , Nilsson Cecilia , Honarpisheh Hedieh , Cserni Gabor , Dent Jo , Fulford Laura , Jordan Lee B. , Jones J. Louise , Kanthan Rani , Litwiniuk Maria , Di Benedetto Anna , Mottolese Marcella , Provenzano Elena , Shousha Sami , Stephens Mark , Walker Rosemary A. , Kulka Janina , Ellis Ian O. , Jeffery Margaret , Thygesen Helene H. , Cappelletti Vera , Daidone Maria G. , Hedenfalk Ingrid A. , Fjällskog Marie-Louise , Melisi Davide , Stead Lucy F. , Shaaban Abeer M. , Speirs Valerie
Published: April 2023

Relationship between eIF4E, eIF5 and clinico-pathological parameters
Interrogation of Oncomine{trade mark, serif} from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
Authors: Humphries Matthew P. , Sundara Rajan Sreekumar , Droop Alastair , Suleman Charlotte A.B. , Carbone Carmine , Nilsson Cecilia , Honarpisheh Hedieh , Cserni Gabor , Dent Jo , Fulford Laura , Jordan Lee B. , Jones J. Louise , Kanthan Rani , Litwiniuk Maria , Di Benedetto Anna , Mottolese Marcella , Provenzano Elena , Shousha Sami , Stephens Mark , Walker Rosemary A. , Kulka Janina , Ellis Ian O. , Jeffery Margaret , Thygesen Helene H. , Cappelletti Vera , Daidone Maria G. , Hedenfalk Ingrid A. , Fjällskog Marie-Louise , Melisi Davide , Stead Lucy F. , Shaaban Abeer M. , Speirs Valerie
Published: April 2023

Interrogation of Oncomine{trade mark, serif} (https://www.oncomine.org/) showed higher expression of eIF4E and eIF5 in breast (top panel) and lung cancer (bottom panel) compared to normal tissue. When these biomarkers were compared for gender, eIF4E and eIF5 expression was proportionately higher in male breast cancer (A, C) but not in lung cancer (B, D), respectively .
Figure S3 from A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Authors: Singh Anurag K. , Winslow Timothy B. , Kermany Mohammad Habiby , Goritz Vincent , Heit Lilia , Miller Austin , Hoffend Nicholas C. , Stein Leighton C. , Kumaraswamy Lalith K. , Warren Graham W. , Bshara Wiam , Odunsi Kunle , Matsuzaki Junko , Abrams Scott I. , Schwaab Thomas , Muhitch Jason B.
Published: April 2023

Supplementary figure S3 shows gating strategy and isotype staining of live tumor cells used for patient samples.
Supplementary Table 1 from Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy
Authors: Bloch Orin , Lim Michael , Sughrue Michael E. , Komotar Ricardo J. , Abrahams John M. , O'Rourke Donald M. , D'Ambrosio Anthony , Bruce Jeffrey N. , Parsa Andrew T.
Published: April 2023

Criteria for determining first progression of GBM: modified from Response Assessment in Neuro-Oncology (RANO) criteria
Supplementary Movie S4 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Authors: Jiao Shiping , Xia Weiya , Yamaguchi Hirohito , Wei Yongkun , Chen Mei-Kuang , Hsu Jung-Mao , Hsu Jennifer L. , Yu Wen-Hsuan , Du Yi , Lee Heng-Huan , Li Chia-Wei , Chou Chao-Kai , Lim Seung-Oe , Chang Shih-Shin , Litton Jennifer , Arun Banu , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PARPi treatment enhances resistance to activated T-cell killing. Time-lapse video of 231 (Nuc-RFP) cells with olaparib treatment co-cultured with activated PBMCs taken using the IncuCyte Zoom microscope.
Figure S3 from Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Authors: Biktasova Asel , Hajek Michael , Sewell Andrew , Gary Cyril , Bellinger Gary , Deshpande Hari A. , Bhatia Aarti , Burtness Barbara , Judson Benjamin , Mehra Saral , Yarbrough Wendell G. , Issaeva Natalia
Published: April 2023

Fold change in the expression of HPV genes in SCC090 cells after 5-aza treatment, as determined by qRT-PCR
Supplementary Movie S2 from PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
Authors: Jiao Shiping , Xia Weiya , Yamaguchi Hirohito , Wei Yongkun , Chen Mei-Kuang , Hsu Jung-Mao , Hsu Jennifer L. , Yu Wen-Hsuan , Du Yi , Lee Heng-Huan , Li Chia-Wei , Chou Chao-Kai , Lim Seung-Oe , Chang Shih-Shin , Litton Jennifer , Arun Banu , Hortobagyi Gabriel N. , Hung Mien-Chie
Published: April 2023

PARPi treatment inhibits cell proliferation of MDA-MB-231 cells. Time-lapse video of 231 (Nuc-RFP) cells with olaparib taken using the IncuCyte Zoom microscope.
Figure S3 from Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer
Authors: Suzawa Ken , Offin Michael , Lu Daniel , Kurzatkowski Christopher , Vojnic Morana , Smith Roger S. , Sabari Joshua K. , Tai Huichun , Mattar Marissa , Khodos Inna , de Stanchina Elisa , Rudin Charles M. , Kris Mark G. , Arcila Maria E. , Lockwood William W. , Drilon Alexander , Ladanyi Marc , Somwar Romel
Published: April 2023

Trametinib synergizes with MET inhibitors in cells with concurrent METexon14 alteration and KRAS mutation.
Supplementary data from Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer
Authors: Liu Jin , Agopiantz Mikaël , Poupon Joël , Wu Zherui , Just Pierre-Alexandre , Borghese Bruno , Ségal-Bendirdjian Evelyne , Gauchotte Guillaume , Gompel Anne , Forgez Patricia
Published: April 2023

Supplemental information about the method and materials used in our experiments.
Suppl. Figure legends from Impact of Blood–Brain Barrier Integrity on Tumor Growth and Therapy Response in Brain Metastases
Authors: Osswald Matthias , Blaes Jonas , Liao Yunxiang , Solecki Gergely , Gömmel Miriam , Berghoff Anna S. , Salphati Laurent , Wallin Jeffrey J. , Phillips Heidi S. , Wick Wolfgang , Winkler Frank
Published: April 2023

Suppl. Figure legends
Supplementary Figure 4 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Authors: Moreno Laura , Perez Cristina , Zabaleta Aintzane , Manrique Irene , Alignani Diego , Ajona Daniel , Blanco Laura , Lasa Marta , Maiso Patricia , Rodriguez Idoia , Garate Sonia , Jelinek Tomas , Segura Victor , Moreno Cristina , Merino Juana , Rodriguez-Otero Paula , Panizo Carlos , Prosper Felipe , San-Miguel Jesus F. , Paiva Bruno
Published: April 2023

Supplementary Figure 4